BLFS Stock - BioLife Solutions, Inc.
Unlock GoAI Insights for BLFS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $82.25M | $143.27M | $76.24M | $119.16M | $48.09M |
| Gross Profit | $53.67M | $46.75M | $53.82M | $37.75M | $27.44M |
| Gross Margin | 65.3% | 32.6% | 70.6% | 31.7% | 57.1% |
| Operating Income | $-7,129,000 | $-70,825,000 | $-5,923,000 | $-35,160,000 | $-3,332,000 |
| Net Income | $-20,184,000 | $-66,427,000 | $-139,805,000 | $-8,908,000 | $2.67M |
| Net Margin | -24.5% | -46.4% | -183.4% | -7.5% | 5.5% |
| EPS | $-0.44 | $-1.52 | $-3.29 | $-0.23 | $0.07 |
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 22nd 2025 | Stephens | Resumed | Overweight | $30 |
| September 30th 2024 | H.C. Wainwright | Initiation | Buy | $29 |
| April 4th 2024 | Jefferies | Initiation | Buy | $22 |
| July 11th 2023 | Craig Hallum | Initiation | Buy | $29 |
| April 25th 2022 | Oppenheimer | Upgrade | Outperform | $28 |
Earnings History & Surprises
BLFSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.02 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.00 | — | — | — |
Q3 2025 | Aug 7, 2025 | $-0.02 | $-0.33 | -1556.7% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.03 | $0.04 | +233.3% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.06 | $-0.01 | +83.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.09 | $-0.02 | +77.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.14 | $-0.06 | +57.1% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.26 | $-0.19 | +26.9% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.36 | $-0.30 | +16.7% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.38 | $-0.67 | -76.3% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.18 | $-0.23 | -27.8% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.20 | $-0.32 | -60.0% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.19 | $-1.15 | -505.3% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.18 | $-0.23 | -27.8% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.20 | $-1.71 | -755.0% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.24 | $-0.17 | +29.2% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.16 | $-0.37 | -131.3% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.09 | $0.00 | +102.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.05 | $0.19 | +480.0% | ✓ BEAT |
Latest News
HC Wainwright & Co. Reiterates Buy on BioLife Solutions, Maintains $32 Price Target
📈 PositiveBioLife Solutions shares are trading lower after the company reported Q3 financial results and cut it sFY25 sales guidance below estimates.
📉 NegativeBioLife Solutions Lowers FY2025 Sales Guidance from $100.000M-$103.000M to $95.000M-$96.000M vs $101.322M Est
📉 NegativeBioLife Solns Q3 Adj. EPS $0.04 Beats $(0.01) Estimate, Sales $28.067M Beat $25.693M Estimate
📈 PositiveBioLife Solutions Sells Cold Chain Logistics Subsidiary, SAVSU Cleo Technologies, For $25.5M In Cash To Peli BioThermal
📈 PositiveFrequently Asked Questions about BLFS
What is BLFS's current stock price?
What is the analyst price target for BLFS?
What sector is BioLife Solutions, Inc. in?
What is BLFS's market cap?
Does BLFS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BLFS for comparison